This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Rite Aid Joins Fight Against COVID-19 by Expanding Services
by Zacks Equity Research
In the wake of the COVID-19 crisis, Rite Aid (RAD) is gearing up to serve customers better by providing home delivery and pick-up services.
The Zacks Analyst Blog Highlights: JPMorgan Chase, Mastercard, Qualcomm, Petrobras and Walgreens Boots Alliance
by Zacks Equity Research
The Zacks Analyst Blog Highlights: JPMorgan Chase, Mastercard, Qualcomm, Petrobras and Walgreens Boots Alliance
Walgreens' Reimbursement Issue Mars Growth, Kroger Pact Aids
by Zacks Equity Research
Persistent reimbursement pressure and adverse mix associated with brand inflation hampers Walgreens' (WBA) bottom-line performance.
Walgreens Adopts New Measures to Fight Against Coronavirus
by Zacks Equity Research
Walgreens (WBA) collaborates with industry partners and healthcare administrators to provide greater access to government-run COVID-19 testing facilities.
Top Analyst Reports for JPMorgan, Mastercard & Qualcomm
by Mark Vickery
Today's Research Daily features new research reports on 12 major stocks, including JPMorgan Chase (JPM), Mastercard (MA) and Qualcomm (QCOM).
Dow Logs Worst One-Day Slump in History: ETF & Stock Winners
by Sanghamitra Saha
Dow Jones saw the worst single-day slump on Thursday. While inverse Dow Jones ETFs gained considerably, these stocks too were less hurt.
Walgreens U.S. Retail Pharmacy Rises Amid Reimbursement Woes
by Zacks Equity Research
Intensifying competition in the U.S. retail drugstore market prompts Walgreens Boots (WBA) to diversify its product offerings.
Walgreens (WBA) Down 2.2% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Walgreens (WBA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Pharmacies & Drug Stores Industry Outlook: Prospects Mixed
by Urmimala Biswas
The Retail - Pharmacies and Drug Stores industry is known for heavy consolidations.
McKesson (MCK) to Report Q3 Earnings: What's in the Offing?
by Zacks Equity Research
McKesson's (MCK) core U.S. Pharmaceutical and Specialty Solutions unit is expected to reflect in fiscal Q3 results.
Company News for Jan 9, 2020
by Zacks Equity Research
Companies In The News Are: LTHM, NEWA, APLT, WBA
Walgreens Boots (WBA) Q1 Earnings Lag Estimates, Margins Fall
by Zacks Equity Research
Sluggishness in Walgreens Boots' (WBA) Retail Pharmacy International segment and margin contractions put pressure on the bottom line during Q1.
Can Value Investors Choose Walgreens Boots (WBA) Stock?
by Zacks Equity Research
Let's see if Walgreens Boots (WBA) stock is a good choice for value-oriented investors right now from multiple angles.
Walgreens Boots Alliance (WBA) Lags Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Walgreens (WBA) delivered earnings and revenue surprises of -2.14% and -0.84%, respectively, for the quarter ended November 2019. Do the numbers hold clues to what lies ahead for the stock?
Lennar, Walgreens, Constellation, JPMorgan and Citigroup are part of Zacks Earnings Preview
by Zacks Equity Research
Lennar, Walgreens, Constellation, JPMorgan and Citigroup are part of Zacks Earnings Preview
Walgreens Boots (WBA) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
Higher comparable pharmacy sales and expanded comparable prescription volume are likely to have aided growth in Walgreens Boots' (WBA) Retail Pharmacy USA during the first quarter of fiscal 2020.
Q4 Earnings Season Preview
by Sheraz Mian
By the time JPMorgan (JPM), Wells Fargo (WFC) and Citigroup (C) come out with their December-quarter results January 14th, we will have seen Q4 results from 20 S&P 500 members already.
Analysts Estimate Walgreens Boots Alliance (WBA) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Walgreens (WBA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The Zacks Analyst Blog Highlights: Apple, Microsoft, Visa, Walgreens and Amazon
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Apple, Microsoft, Visa, Walgreens and Amazon
As 2019 Winds Up, Here're the Best & Worst Dow Stocks
by Tirthankar Chakraborty
While Apple has been the best performing stock in the Dow so far this year, the worst performer is Walgreens Boots. Though the rankings may differ before the close of 2019, the stories behind the stocks won't.
Rite Aid (RAD) Earnings Surpass Estimates in Q3, Stock Up
by Zacks Equity Research
Rite Aid (RAD) posts robust results in third-quarter fiscal 2020. Notably, the bottom line benefits from higher adjusted EBITDA in the quarter.
Stocks Hit Records, Nike Earnings & Buy this Biofuel Stock - Free Lunch
by Benjamin Rains
The House voted to impeach President Trump. Why 2020 could be another strong year for stocks before we preview Nike earnings. The episode then closes with why Enviva Partners (EVA) is a Zacks Rank #1 (Strong Buy) stock right now...
Walgreens Boots Alliance (WBA) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Walgreens Boots Alliance (WBA) closed at $57.80 in the latest trading session, marking a -0.14% move from the prior day.
Walgreens is the Worst Dow Stock Now, Will 2020 Be Different?
by Zacks Equity Research
Despite the dismal performance in recent times, Walgreens (WBA) has chances to bounce back in 2020.
McKesson, Walgreens Form JV for European Pharmaceutical Unit
by Zacks Equity Research
The VA selects McKesson (MCK) as their prime pharmaceutical supplier.